同时,与EGFR野生型NSCLC相比,EGFR突变NSCLC中HER3的表达也较高。Patritumab deruxtecan(U3-1402,HER3-DXd)是一种新型的、正在研究中的靶向HER3的抗体偶联药物(ADC)。U31402-A-U102 Ⅰ期研究发现,HER3-DXd在具有多种已知或未知E...
Daiichi Sankyo App is intended for use collect patient reported outcomes relating to a clinical trial. Patients must be given accounts by a participating site i…